Exact Sciences' Cologuard Now Recommended in ACS Guidelines | GenomeWeb

NEW YORK (GenomeWeb) — Exact Sciences today announced that the American Cancer Society's national guidelines on colorectal cancer prevention and early detection have been updated to reflect the commercial availability of the company's Cologuard cancer screening test.

Cologuard detects cancer-associated mutations and blood biomarkers in stool samples and has been shown to identify 92 percent of colorectal cancers in average risk patients with 87 percent specificity using only a single sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.